JP2022520997A5 - - Google Patents

Info

Publication number
JP2022520997A5
JP2022520997A5 JP2021549213A JP2021549213A JP2022520997A5 JP 2022520997 A5 JP2022520997 A5 JP 2022520997A5 JP 2021549213 A JP2021549213 A JP 2021549213A JP 2021549213 A JP2021549213 A JP 2021549213A JP 2022520997 A5 JP2022520997 A5 JP 2022520997A5
Authority
JP
Japan
Application number
JP2021549213A
Other languages
Japanese (ja)
Other versions
JP2022520997A (ja
JPWO2020172485A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019142 external-priority patent/WO2020172485A1/en
Publication of JP2022520997A publication Critical patent/JP2022520997A/ja
Publication of JPWO2020172485A5 publication Critical patent/JPWO2020172485A5/ja
Publication of JP2022520997A5 publication Critical patent/JP2022520997A5/ja
Pending legal-status Critical Current

Links

JP2021549213A 2019-02-22 2020-02-21 イミプリドンを使用する方法 Pending JP2022520997A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962809140P 2019-02-22 2019-02-22
US62/809,140 2019-02-22
US201962908105P 2019-09-30 2019-09-30
US62/908,105 2019-09-30
PCT/US2020/019142 WO2020172485A1 (en) 2019-02-22 2020-02-21 Methods of using imipridones

Publications (3)

Publication Number Publication Date
JP2022520997A JP2022520997A (ja) 2022-04-04
JPWO2020172485A5 JPWO2020172485A5 (https=) 2023-02-20
JP2022520997A5 true JP2022520997A5 (https=) 2023-02-20

Family

ID=72144740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549213A Pending JP2022520997A (ja) 2019-02-22 2020-02-21 イミプリドンを使用する方法

Country Status (3)

Country Link
US (1) US20220143024A1 (https=)
JP (1) JP2022520997A (https=)
WO (1) WO2020172485A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228047B2 (en) * 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
EP4337214A4 (en) * 2021-05-13 2025-01-29 Chimerix, Inc. USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMAS
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
WO2024199457A1 (zh) * 2023-03-31 2024-10-03 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
WO2025250553A1 (en) * 2024-05-28 2025-12-04 Chimerix, Inc. Solid state forms of imipridone derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925251B2 (en) * 2011-10-19 2018-03-27 President And Fellows Of Harvard College Treatments for Mycobacterium tuberculosis
PL3408298T3 (pl) * 2016-01-29 2025-03-31 Oncoceutics, Inc. Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr)
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022521797A5 (https=)
JP2022520997A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)